NEW YORK (Reuters Health) – Taken together, non-drug and drug costs of the two approved chimeric antigen receptor T-cell (CAR-T) immunotherapies could result in annual expenditures of more than $3 billion for the U.S. healthcare system, researchers say.

Dr. Immaculada Hernandez of the University of Pittsburgh School of Pharmacy and colleagues evaluated drug and non-drug costs of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) using various clinical scenarios.

Read the full story here